BioSpace News Archive

Radiosynthesis modules are offered as automated equipment for dispersed settings for the formulation as well as production of radiotracers.

Touchlight, the leading synthetic DNA manufacturer, is collaborating with the Vanderbilt Vaccine Center at Vanderbilt University Medical Center as part of the DARPA P3 programme.

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the second quarter ended July 3, 2021.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, reported financial results for the second quarter ending June 30, 2021.

Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced corporate updates and financial results for the first quarter of fiscal year 2021.

Pfizer Inc. reported financial results for second-quarter 2021 and raised 2021 guidance for revenues and Adjusted diluted EPS driven by its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE COVID-19 vaccine, as well as its business excluding BNT162b2.

ALX Oncology Holdings Inc. in partnership with Merck, known as MSD outside the United States and Canada, announced the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA®, Merck’s anti-PD-1 therapy, and standard chemotherapy for the treatment of patients with advanced head and neck squamous cell carcinoma.

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that Jake Bauer joined the company’s Board of Directors as an independent director.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced it will release its second quarter 2021 financial results on Tuesday, August 10, 2021 before the open of the U.S. financial markets.

HUTCHMED Limited, the innovative, commercial-stage biopharmaceutical company, reports its unaudited financial results for the six months ended June 30, 2021 and provides updates on key clinical and commercial developments since the start of the year.